In recent decades, the interest in the Emericellopsis genus as producers of bioactive molecules has increased significantly due to the isolation of new compounds with potential pharmaceutical applications. The species of this genus produce a spectrum of peptide antibiotics with antibacterial and antifungal activity.

Evaluation of the spectrum of antibiotic activity has allowed us to choose a promising producer of new antibacterial compounds, the Emericellopsis sp. E102 strain derived from saline soils. Strain E102, based on molecular and phylogenetic constructions, is allocated into a separate clade within the marine clade of Emericellopsis and is presumably a new species. In this research, three previously undescribed compounds were isolated from the fungal strain E102, grown in both Czapek–Dox and PDB liquid culture media. The ethyl acetate extract of the E102 strain demonstrated significant efficacy against a concentration of 1,000 μg/mL, resulting in inhibition zones measuring 20 - 30 mm against Escherichia coli, ATCC 25922; Klebsiella pneumonia, ATCC 700603; Pseudomonas aeruginosa, ATCC 27853; Bacillus subtilis, АТСС 6633; Staphylococcus aureus, ATCC 29213; and Enterococcus faecalis, ATCC 29212. Based on HPLC separation of the ethanol concentrates, an active compound was obtained and investigated further. The monoisotopic mass of the compound, determined using MS, was 724.5 g/mol. Using the Chemcalc.org service, the most probable gross formulas ffor the required component were determined. Based on the calculations presented, there is a high probability that the substance has a sterane framework.

The work of Vladimir V. Sokolov and Marina L. Georgieva was supported by the Russian Science Foundation (grant #25-24-00291). The work of Ivan V. Mironov was carried out with institutional funding from the Gause Institute of New Antibiotics.